Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9167)
All Articles published online
|
Publishing Process of This Article
|
May 21, 2015 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mei WQ, Hu HZ, Liu Y, Li ZC, Wang WG. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World J Gastroenterol 2015; 21(19): 6044-6051 [PMID: 26019471 DOI: 10.3748/wjg.v21.i19.6044] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i19/6044.htm |
| Number | Citing Articles |
| 1 |
Anna Pękala, Rafał Filip. Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study. Journal of Clinical Medicine 2021; 10(22): 5311 doi: 10.3390/jcm10225311
|
| 2 |
Masafumi Nishio, Yoshito Ishii, Yu Hashimoto, Haruka Otake, Tsuyoshi Ogashiwa, Saya Tsuda, Hisae Yasuhara, Yusuke Saigusa, Hideaki Kimura, Shin Maeda, Reiko Kunisaki. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. Scandinavian Journal of Gastroenterology 2018; 53(10-11): 1236 doi: 10.1080/00365521.2018.1511825
|
| 3 |
Sean Stern, Alexandra J. Ward, Catherine Saint-Laurent Thibault, Fernando Camacho, Elham Rahme, Dominik Naessens, Guy Aumais, Edmond-Jean Bernard, Raymond Bourdages, Albert Cohen, Pierre Pare, Peter Dyrda. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. Journal of Medical Economics 2018; 21(1): 27 doi: 10.1080/13696998.2017.1371033
|
| 4 |
Margalida Calafat, Paola Torres, Joan Tosca-Cuquerella, Rubén Sánchez-Aldehuelo, Montserrat Rivero, Marisa Iborra, María González-Vivo, Isabel Vera, Luisa de Castro, Luis Bujanda, Manuel Barreiro-de Acosta, Carlos González-Muñoza, Xavier Calvet, José Manuel Benítez, Mónica Llorente-Barrio, Gerard Surís, Fiorella Cañete, Lara Arias-García, David Monfort, Andrés Castaño-García, Francisco Javier Garcia-Alonso, José M. Huguet, Ignacio Marín-Jímenez, Rufo Lorente, Albert Martín-Cardona, Juan Ángel Ferrer, Patricia Camo, Javier P. Gisbert, Ramón Pajares, Fernando Gomollón, Jesús Castro-Poceiro, Jair Morales-Alvarado, Jordina Llaó, Andrés Rodríguez, Cristina Rodríguez, Pablo Pérez-Galindo, Mercè Navarro, Nuria Jiménez-García, Marta Carrillo-Palau, Isabel Blázquez-Gómez, Eva Sesé, Pedro Almela, Patricia Ramírez de la Piscina, Carlos Taxonera, Iago Rodríguez-Lago, Lidia Cabrinety, Milagros Vela, Miguel Mínguez, Francisco Mesonero, María José García, Mariam Aguas, Lucía Márquez, Marisol Silva Porto, Juan R. Pineda, Koldo García-Etxebarría, Federico Bertoletti, Eduard Brunet, Míriam Mañosa, Eugeni Domènech. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848231221713
|
| 5 |
Yenan Fang, Bingyan Shen, Qin Dai, Qiqi Xie, Wencan Wu, Min Wang. Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment. European Journal of Medical Research 2023; 28(1) doi: 10.1186/s40001-023-01330-0
|
| 6 |
Caroline Meyer Olesen, Mehmet Coskun, Laurent Peyrin-Biroulet, Ole Haagen Nielsen. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology & Therapeutics 2016; 159: 110 doi: 10.1016/j.pharmthera.2016.01.001
|
| 7 |
S. Renna, E. Orlando, F. S. Macaluso, M. Maida, M. Affronti, M. Giunta, C. Sapienza, G. Rizzuto, R. Orlando, M. Dimarco, M. Cottone, A. Orlando. Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Alimentary Pharmacology & Therapeutics 2016; 44(3): 310 doi: 10.1111/apt.13692
|
| 8 |
N. N. Potekaev, O. V. Zhukova, S. I. Artemyeva. Psoriasis: a personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologies. Meditsinskiy sovet = Medical Council 2020; (12): 28 doi: 10.21518/2079-701X-2020-12-28-34
|
| 9 |
Hélène Vallet, Pascal Seve, Lucie Biard, Jean Baptiste Fraison, Philip Bielefeld, Laurent Perard, Boris Bienvenu, Sébastien Abad, Aude Rigolet, Alban Deroux, Damien Sene, Antoinette Perlat, Isabelle Marie, Elodie Feurer, Eric Hachulla, Olivier Fain, Gaëlle Clavel, Sophie Riviere, Pierre‐Alban Bouche, Julie Gueudry, Gregory Pugnet, Phuc Le Hoang, Matthieu Resche Rigon, Patrice Cacoub, Bahram Bodaghi, David Saadoun. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis & Rheumatology 2016; 68(6): 1522 doi: 10.1002/art.39667
|
| 10 |
Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Raquel Montoiro-Allué, Alejandro López-Del Val. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 2018; 18(3): 321 doi: 10.1080/14737167.2018.1411193
|
| 11 |
Katerina Pantavou, Anneza I Yiallourou, Daniele Piovani, Despo Evripidou, Silvio Danese, Laurent Peyrin-Biroulet, Stefanos Bonovas, Georgios K Nikolopoulos. Efficacy and safety of biologic agents and tofacitinib in moderate‐to‐severe ulcerative colitis: A systematic overview of meta‐analyses. United European Gastroenterology Journal 2019; 7(10): 1285 doi: 10.1177/2050640619883566
|
| 12 |
Brigida Barberio, Fabiana Zingone, Leonardo Frazzoni, Renata D’Incà, Maria Chiara Maccarone, Matteo Ghisa, Davide Massimi, Greta Lorenzon, Edoardo Vincenzo Savarino. Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. Digestive Diseases 2021; 39(1): 16 doi: 10.1159/000508865
|
| 13 |
Adrian D. Vickers, Claire Ainsworth, Reema Mody, Annika Bergman, Caroline S. Ling, Jasmina Medjedovic, Michael Smyth, John Green. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLOS ONE 2016; 11(10): e0165435 doi: 10.1371/journal.pone.0165435
|
| 14 |
Scott M. Whitlock, Clinton W. Enos, April W. Armstrong, Alice Gottlieb, Richard G. Langley, Mark Lebwohl, Joseph F. Merola, Caitriona Ryan, Michael P. Siegel, Jeffrey M. Weinberg, Jashin J. Wu, Abby S. Van Voorhees. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2018; 78(2): 383 doi: 10.1016/j.jaad.2017.06.043
|
| 15 |
Jixiang Zhang, Xiaohan Wu, Shuchun Wei, Chuan Liu, Xiaoli Wang, Weiguo Dong. Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis. Autoimmunity 2022; 55(8): 538 doi: 10.1080/08916934.2022.2103803
|
| 16 |
Yiru Zhou, Ruihua Fan, Benson O. A. Botchway, Yong Zhang, Xuehong Liu. Infliximab Can Improve Traumatic Brain Injury by Suppressing the Tumor Necrosis Factor Alpha Pathway. Molecular Neurobiology 2021; 58(6): 2803 doi: 10.1007/s12035-021-02293-1
|
| 17 |
Cheng-mei Tian, Mei-feng Yang, Hao-ming Xu, Min-zheng Zhu, Yuan Zhang, Jun Yao, Li-sheng Wang, Yu-jie Liang, De-feng Li, Shuiqiao Yuan. Mesenchymal Stem Cell-derived Exosomes: Novel Therapeutic Approach for Inflammatory Bowel Diseases. Stem Cells International 2023; 2023: 1 doi: 10.1155/2023/4245704
|
| 18 |
Sara Renna, Filippo Mocciaro, Marco Ventimiglia, Rosalba Orlando, Fabio Salvatore Macaluso, Maria Cappello, Walter Fries, Marco Mendolaro, Antonino Carlo Privitera, Concetta Ferracane, Valentina Pisana, Antonio Magnano, Dario Pluchino, Gaetano Inserra, Giuseppe Scarpulla, Serena Garufi, Antonio Carroccio, Sebastiano Siringo, Roberto Di Mitri, Mario Cottone, Ambrogio Orlando. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Digestive and Liver Disease 2018; 50(12): 1292 doi: 10.1016/j.dld.2018.06.008
|
| 19 |
Gabriele Dragoni, Marco Le Grazie, Beatrice Orlandini, Francesca Rogai. Golimumab in inflammatory bowel diseases: present and future scenarios. Clinical Journal of Gastroenterology 2019; 12(1): 1 doi: 10.1007/s12328-018-0906-9
|
| 20 |
Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Santiago García-López, Alejandro López-Del Val. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. International Journal of Clinical Pharmacy 2018; 40(6): 1411 doi: 10.1007/s11096-018-0743-4
|
| 21 |
A. Cholapranee, G. S Hazlewood, G. G. Kaplan, L. Peyrin‐Biroulet, A. N. Ananthakrishnan. Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Alimentary Pharmacology & Therapeutics 2017; 45(10): 1291 doi: 10.1111/apt.14030
|